HPR19 Variation in Medicaid and Commercial Coverage of Cell and Gene Therapies

Abstract

Cell and gene therapies (CGTs) are potentially curative treatments for a growing array of diseases. CGTs pose a particular challenge to health care payers due to their one-time administration, high costs and uncertain long-term benefits. Most patients who are eligible for CGTs are covered by Medicaid or Commercial health plans. In this study we assessed variation in Medicaid and Commercial coverage for 11 CGTs.